scholarly journals Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis

2016 ◽  
Vol 48 (2) ◽  
pp. 843-847 ◽  
Author(s):  
Won-Young Park ◽  
Han-Jo Kim ◽  
Kyoungha Kim ◽  
Sang-Byung Bae ◽  
Namsu Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Leptomeningeal Carcinomatosis ◽  
Trastuzumab Treatment ◽  
Intrathecal Trastuzumab

scholarly journals Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer

Medicine ◽  
2020 ◽  
Vol 99 (1) ◽  
pp. e18298 ◽  
Author(s):  
Francisco José Valdivia García ◽  
Natalia Palazón Carrión ◽  
Luis de la Cruz-Merino
Keyword(s):  
Breast Cancer ◽  
Complete Response ◽  
Leptomeningeal Carcinomatosis ◽  
Intrathecal Trastuzumab

Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab

2011 ◽  
Vol 127 (3) ◽  
pp. 841-844 ◽  
Author(s):  
Mafalda Oliveira ◽  
Sofia Braga ◽  
José Luís Passos-Coelho ◽  
Ricardo Fonseca ◽  
João Oliveira
Keyword(s):  
Breast Cancer ◽  
Complete Response ◽  
Leptomeningeal Carcinomatosis ◽  
Intrathecal Trastuzumab

scholarly journals Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Cristina Dumitrescu ◽  
Dominique Lossignol
Keyword(s):  
Breast Cancer ◽  
Growth Factor Receptor ◽  
Neurological Status ◽  
Leptomeningeal Carcinomatosis ◽  
Neoplastic Meningitis ◽  
Her2 Positive ◽  
Epidermal Growth ◽  
Promising Treatment ◽  
Intrathecal Trastuzumab ◽  
Positive Breast Cancer

We report the case of a 65-year-old woman, diagnosed with a breast cancer human epidermal growth factor receptor (HER2) previously negative, who developed leptomeningeal carcinomatosis and was treated with intrathecal (IT) trastuzumab (TST). After five doses of IT trastuzumab, at escalading doses, once weekly, the patient's neurological status stabilised, and that result was maintained for two months. There is evidence in the literature that breast cancer receptor status may change over time, and when it occurs, it may modify the therapeutical approach. We reviewed the pertinent literature and concluded that IT trastuzumab might be a promising treatment for patients with HER2-positive breast cancer leptomeningeal carcinomatosis.

scholarly journals UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells

2021 ◽  
Author(s):  
Jun Hua ◽  
Zhe Zhang ◽  
Lili Zhang ◽  
Yan Sun ◽  
Yuan Yuan
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Neoadjuvant Therapy ◽  
Needle Biopsy ◽  
Breast Cancer Cells ◽  
Her2 Positive ◽  
Trastuzumab Treatment ◽  
Her2 Positive Breast Cancer ◽  
Trastuzumab Therapy ◽  
Positive Breast Cancer

Abstract Purpose This study aimed to investigate the possibility of UCP-2 inhibitor in reducing acquired resistance of trastuzumab to improve the outcome of patients receiving trastuzumab therapy by exploring the relationship between UCP-2 expression and HER2 signaling pathway and examining whether UCP-2 expression was modulated by trastuzumab treatment. Methods 32 women diagnosed with primary HER2-positive breast cancer were recruited in this study. Needle biopsy was obtained from patients before they received at least four cycles neoadjuvant therapy containing trastuzumab in combination with chemotherapy. Surgical tumor biopsy was obtained during surgical procedure after the neoadjuvant therapy. Levels of HER2 phosphorylation and UCP-2 expression were detected by immunohistochemistry (IHC) and compared between tumor needle biopsy tissue and surgical tumor samples of these patients, as well as in BT474 breast cancer cells before and after trastuzumab treatment. HER2-selective phosphorylation/kinase activity inhibitor ONT-380 was used to identify the correlation between HER2 phosphorylation level and UCP-2 expression. UCP-2 inhibitor Genipin was then used to evaluate the apoptosis index in BT474 cells treated with trastuzumab. Results UCP-2 expression was significantly elevated in surgical tumor samples from breast cancer patients receiving trastuzumab in a neoadjuvant setting. We further confirmed our findings in HER2-positive BT474 cell line and found that trastuzumab treatment induced phosphorylation of HER2 and the overexpression of UCP-2, and the latter can be reversed by HER2 selective kinase inhibitor ONT-380. Moreover, UCP-2 inhibitor Genipin significantly enhanced the proliferation suppression effects of trastuzumab and markedly promoted apoptosis. Conclusion Taken together, our study identified UCP-2 as a novel therapeutic target for HER2 positive breast cancer and UCP-2 inhibitor may have great potential to enhance the response rate and efficacy of trastuzumab therapy.

Isolated Leptomeningeal Carcinomatosis (Carcinomatous Meningitis) after Taxane-Induced Major Remission in Patients with Advanced Breast Cancer

Oncology ◽  
2002 ◽  
Vol 63 (1) ◽  
pp. 6-15 ◽  
Author(s):  
Christos Kosmas ◽  
Nikolaos A. Malamos ◽  
Nikolas B. Tsavaris ◽  
Melina Stamataki ◽  
Achilleas Gregoriou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Leptomeningeal Carcinomatosis ◽  
Advanced Breast ◽  
Carcinomatous Meningitis

Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients

2021 ◽  
Author(s):  
Ann Banke ◽  
Morten Schou ◽  
Marianne Ewertz ◽  
Jordi Dahl ◽  
Peter Hartmund Frederiksen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Longitudinal Strain ◽  
Global Longitudinal Strain ◽  
Breast Cancer Patients ◽  
Trastuzumab Treatment

scholarly journals Paclitaxel and trastuzumab treatment affects insulin growth factor I expression in breast cancer cell lines

2015 ◽  
Vol 10 (4) ◽  
pp. 799 ◽  
Author(s):  
Yu-Xian Qian ◽  
Rui Yu ◽  
Shi-Rong Qin
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Growth Factor ◽  
Cell Cycle Arrest ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Breast Cancer Cell Lines ◽  
Factor I ◽  
Trastuzumab Treatment ◽  
Cycle Arrest

<p class="Abstract">Breast cancer is the most common type of cancers and second primary cause of death among women. Insulin-like growth factor I (IGF-1) signaling pathway plays a vital role in cancer cell survival, proliferation, chemotaxis and angiogenesis. In this study, the effect of combination of two drugs, paclitaxel and trastuzumab on IGF signaling and cell cycle arrest in breast cancer cell lines, T47D and Hs0578T were explored. The interaction of paclitaxel and trastuzumab on IGF-1 signaling pathway was studied with IGF-1 and phosphoinositide 3-kinase inhibitor, LY294002. The protein expression of IGF signaling molecules were reduced in the drug treated cancer cells. LY294002 and IGF-1 with paclitaxel and trastuzumab treatment inhibited phosphorylated Akt. During G0/G1 phase, cell cycle arrest and accumulation of apoptotic cells were observed in drug treated cancer cells. The synergistic effect of paclitaxel and trastuzumab decreased the multiplication of breast cancer cells by altering the expression of IGF-I signaling molecules. This combination proves to be one of the useful methods to treat breast cancer.</p><p> </p>

Sign in / Sign up

Export Citation Format

Share Document